Table 1. Baseline demographic and clinical parameters and between visit changes in clinical parameters displayed by treatment group.
| Placebo Group | Spironolactone Group | |||
|---|---|---|---|---|
| Baseline | Between-Visit Change | Baseline | Between-Visit Change | |
| N | 11 | - | 12 | - |
| Mean Age, yr | 41 ± 14 | - | 47 ± 11 | - |
| Female, n (%) | 7 (64%) | - | 7 (58%) | - |
| Premenopausal | 6 (86%) | 3 (43%) | ||
| Race, n (%) | - | - | ||
| Caucasian | 6 (55%) | - | 9 (75%) | - |
| African American | 5 (45%) | - | 3 (25%) | - |
| Mean Arterial Pressure (mmHg) | 88.2 ± 9.9 | 1.9 ± 7.4 | 90.6 ± 6.5 | -4.2 ± 5.6* |
| BMI (kg/m2) | 35.7 ± 5.4 | 0.4 ± 1.3 | 38.5 ± 6.9 | 0.2 ± 0.4 |
| Serum Aldosterone (ng/dL) | 3.2 ± 1.2 | -0.3 ± 1.3 | 3.4 ± 1.5 | 5.2 ± 7.4* |
| Serum Cortisol (mcg/dL) | 7.3 ± 4.1 | 2.4 ± 4.1 | 8.9 ± 3.2 | 0.9 ± 3.7 |
| Serum Potassium (mmol/L) | 4.3 ± 0.5 | 0.0 ± 0.4 | 4.2 ± 0.2 | 0.1 ± 0.4 |
Data are expressed as mean ± SD unless stated otherwise. Changes are calculated as parameter post-treatment minus parameter at baseline for each group. There were no significant clinical differences between treatment and placebo groups pre-randomization; however between-visit changes in serum aldosterone and mean arterial pressure were significantly different across treatment groups.
*
Significant (p<0.05) difference between treatment and placebo groups.